ArticleScientific reports2019
Ras suppressor-1 (RSU-1) promotes cell invasion in aggressive glioma cells and inhibits it in non-aggressive cells through STAT6 phospho-regulation.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 42 citations in OpenAlex.
- Mechanistic insights into cellular deformation enable enhanced extensional-flow cytometry for label-free classification and sorting.Microsystems & nanoengineering · 2026Article
- Lipid metabolism as a marker for glioma aggressiveness.Bioscience reports · 2026Article
- Pharmacological Targeting of Midkine (MDK) Reveals Stiffness-Dependent Control of Hepatocellular Carcinoma Invasiveness.International journal of molecular sciences · 2026Article
- RSU1 Mediates Caco-2 Colorectal Cancer Cells Proliferation and Migration via PI3K/AKT Signaling Pathway.Cell biochemistry and biophysics · 2025Article
- Atomic Force Microscopy-Based Nanomechanical Signatures for Staging Classification and Drug Response in Pulmonary Fibrosis.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- The Young's Modulus as a Mechanical Biomarker in AFM Experiments: A Tool for Cancer Diagnosis and Treatment Monitoring.Sensors (Basel, Switzerland) · 2025Review
- Exploring the heterogeneity in glioblastoma cellular mechanics using in-vitro assays and atomic force microscopy.Scientific reports · 2025Article
- Exploring the Mechanism of Sempervirine Inhibiting Glioblastoma Invasion Based on Network Pharmacology and Bioinformatics.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Zinc-Modified Titanate Nanotubes as Radiosensitizers for Glioblastoma: Enhancing Radiotherapy Efficacy and Monte Carlo Simulations.ACS omega · 2024Article
- ProstaMine: a bioinformatics tool for identifying subtype-specific co-alterations associated with aggressiveness in prostate cancer.Frontiers in pharmacology · 2024Article
- Comprehensive analysis of cell-extracellular matrix protein Ras suppressor-1 in function and prognosis of gastrointestinal cancers.World journal of methodology · 2023Article
- Suppression of sonic hedgehog pathway-based proliferation in glioblastoma cells by small-size silver nanoparticles in vitro.Archives of toxicology · 2023Article
- Gold Nanobipyramids for Near-Infrared Fluorescence-Enhanced Imaging and Treatment of Triple-Negative Breast Cancer.Cancers · 2023Article
- Ras suppressor-1 (RSU1) exerts a tumor suppressive role with prognostic significance in lung adenocarcinoma.Clinical and experimental medicine · 2023Article
- Pancreatic Cancer Presents Distinct Nanomechanical Properties During Progression.Annals of biomedical engineering · 2023Article
- Effect of sunitinib derivatives on glioblastoma single-cell migration and 3D cell cultures.American journal of cancer research · 2023Article
- AQP4-dependent glioma cell features affect the phenotype of surrounding cells via extracellular vesicles.Cell & bioscience · 2022Article
- Nanomechanical and Morphological AFM Mapping of Normal Tissues and Tumors on Live Brain Slices Using Specially Designed Embedding Matrix and Laser-Shaped Cantilevers.Biomedicines · 2022Article
- Strategies for developing complex multi-component in vitro tumor models: Highlights in glioblastoma.Advanced drug delivery reviews · 2022Review
- Aloin decelerates the progression of hepatocellular carcinoma through circ_0011385/miR-149-5p/WT1 axis.Cell cycle (Georgetown, Tex.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most gliomas are invasive tumors formed from glial cells and associated with high mortality rates. In this study, we characterized four glioma cell lines of varying degree of aggressiveness (H4, SW1088, A172 and U87-MG) in terms of morphology, cytoskeleton organization and stiffness, and evaluated their invasive potential by performing invasion, colony forming and spheroid invasion assays. Cells were divided into two distinct groups: aggressive cell lines (A172 and U87-MG) with more elongated, softer and highly invasive cells and less aggressive cells (H4 and SW088). Interestingly, we found that Ras Suppressor-1 (RSU-1), a cell-matrix adhesion protein involved in cancer cell invasion, was significantly upregulated in more aggressive glioma cells compared to less aggressive. Importantly, RSU-1 silencing had opposing effects on glioma cell invasion depending on their aggressiveness, inhibiting migration and invasion of aggressive cells and promoting those of less aggressive cells. Finally, we found that RSU-1 silencing in aggressive cells led to decreased Signal Transducer and Activator of Transcription6 (STAT6) phosphorylation and Matrix Metalloproteinase13 (MMP13) expression in contrast to less invasive cells. Our study demonstrates that RSU-1 promotes invasion of aggressive glioma cells and inhibits it in the non-aggressive cells, indicating that it could serve as a predictor of gliomas progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.